2108
A. Sarkar et al. / Journal of Organometallic Chemistry 693 (2008) 2097–2110
major component and the corresponding bisphosphite (4) as the
minor component. The mixture was dissolved in petrol and the
stirred for 1 h at 25 °C and the solution was evaporated under vac-
uum to obtain the title complex 3e as a colorless solid. 31P{1H}
NMR (CDCl3, 162 MHz): d = 149.7 (s).
solution kept overnight to obtain colorless crystals of
6
(yield = 0.75 g, 36%); m.p = 100–105 °C; 31P{1H} NMR (CDCl3,
162 MHz): d = 147.1 (s); 1H NMR (CDCl3, 400 MHz): d = 0.33 (t,
3H, –C2H5CH3), 0.73 (s, 9H, –C(CH3)3), 0.90 (s, 9H, –C(CH3)3),
1.09 (t, 3H, –C2H5CH3), 1.34 (s, 18H, –C(CH3)3); 1.83(m, 2H,
–C2H5CH3), 1.91 (m, 2H, –C2H5CH3), 3.129 (d, 2J(H,H) = 12.4 Hz,
1H, ArCH2Ar), 3.253 (d, 2J(H,H) = 12.8 Hz, 1 H, ArCH2Ar), 3.321 (d,
2J(H,H) = 10.0 Hz, 1H, ArCH2Ar), 3.354 (d, 2J(H,H) = 9.6 Hz, 1H,
ArCH2Ar), 3.585 (t, 2H, –OCH2C2H5), 3.721 (m, 1H, –OCH2C2H5),
3.85 (m, 1H, –OCH2C2H5), 4.155 (d, 2J(H,H) = 13.6 Hz, 1H, ArCH2Ar),
4.268 (d, 2J(H,H) = 12.4 Hz, 1H, ArCH2Ar), 4.566 (d, 2J(H,H) =
13.2 Hz, 1H, ArCH2Ar), 4.741 (d, 2J(H,H) = 12.8 Hz, 1H, ArCH2Ar),
6.43, 6.45, 6.62, 6.65, 7.05, 7.15 (6s, 8m-ArH, calixarene), 7.28–
7.6 (m, 8H, biphenol ArH). MS (MALDI, M = 947.2): m/z = 985.8
(M + K+, from matrix).
Complexes 3f, 3g, 5a–5c, 6a–6d were synthesized by a proce-
dure similar to that used for the preparation of complex 3e.
4.10. Synthesis of [{(g3-1-Me-C3H4)Pd(Cl)}2(3)] (3f)
Starting materials: [(g3-1-Me-C3H4)PdCl]2 (15 mg, 4 ꢂ 10ꢁ5
mol) and ligand (3) (47 mg, 4 ꢂ 10ꢁ5 mol). Yellow micro-crystals
of 3f were grown from chloroform solution by layering with hex-
ane. (yield = 0.020 g, 62.5%); m.p. = 225–230 °C (dec.); 31P{1H}
NMR (CDCl3, 162 MHz): d = 152.4 (s), 152.5 (s); 1H NMR (CDCl3,
400 MHz): d = 0.04(t, 6H, –C2H5CH3), 0.03 and 0.12 (2t, –C2H5CH3,
other isomers), 0.79, 0.80 (2s, 18H, –C(CH3)3), 1.36 (s, 18H,
–C(CH3)3); 1.54 (m, 4H, –C2H5CH3), 1.62 (2d, 6H, –CH3, CH3C3H4)
3.30–3.64 (m, 4H, –OCH2C2H5, 4H, ArCH2Ar), 3.91 (m, 4H, termi-
nal-CH3C3H4), 4.50–4.58 (m, 4H, ArCH2Ar), 4.62 (m, 2H, terminal-
CH3C3H4), 4.73 (m, 2H, central-CH3C3H4), 6.46, 6.52 (2s, 4H, m-ArH,
calixarene); 7.21, 7.22 (2s, 4H, m-ArH, calixarene), 7.25–7.80 (m,
16H, biphenol ArH). Elemental Anal. Calc. for C82H96O8P2Pd2Cl2: C,
63.3; H, 6.2. Found: C, 63.6; H, 6.2%.
4.5. Synthesis of [(g3-C3H5)Pd(j2-P,P0-3)](PF6) (3a)
Calix[4]arene phosphite (3) (94 mg, 8 ꢂ 10ꢁ5 mol) in acetone
(30 mL) was added drop-wise to a suspension of [(g3-C3H5)PdCl]2
(14 mg, 4 ꢂ 10ꢁ5 mol) and NH4PF6 (15 mg, 8.8 ꢂ 10ꢁ5 mol) in ace-
tone (30 mL) at 0 °C. The reaction mixture was stirred for 1 h at
0 °C and filtered through celite. Solvent was evaporated from the
filtrate. The residue was dissolved in chloroform (3 mL) and hexane
was added slowly until the solution became hazy. The solution was
kept aside for 12 h to obtain colorless precipitate of the title com-
pound (3a). 31P{1H} NMR (CDCl3, 162 MHz): d = 127.2 (s).
4.11. Synthesis of [{(g3-1-Ph-C3H4)Pd(Cl)}2(3)] (3g)
Starting materials: [(g3-1-Ph-C3H4)PdCl]2 (20 mg, 4 ꢂ 10ꢁ5 mol)
and ligand (3) (47 mg, 4 ꢂ 10ꢁ5 mol). 31P{1H} NMR (CDCl3,
162 MHz): d = 152.2 (s).
Complexes 3b–3d, 4a, 4b were synthesized by a procedure sim-
ilar to that used for the preparation of complex 3a.
4.12. Synthesis of [(g3-C3H5)Pd(j2-P,P0-4)](PF6) (4a)
Starting materials: [(g3-C3H5)PdCl]2 (14 mg, 4 ꢂ 10ꢁ5 mol);
NH4PF6 (15 mg, 8.8 ꢂ 10ꢁ5 mol) and ligand (4) (94 mg, 8 ꢂ
10ꢁ5 mol). (yield = 0.005 g, 30%); m.p. = 210–220 °C (dec.), 31P{1H}
NMR (CDCl3, 162 MHz): d = 128.3 (s, minor), 128.8 (s, major)
1H NMR (CDCl3, 400 MHz): d = 0.95 and 1.25 (2s, 18H + 18H,
–C(CH3)3, major); 0.96 and 1.23(2s, 18H + 18H, –C(CH3)3, minor);
1.01(t, 6H, –C2H5CH3, major); 1.07 (t, 6H, –C2H5CH3, minor); 1.97
and 2.1 (2m, 4H, major and 4H minor –C2H5CH3); 2.61, (m, 2H, ter-
minal allyl –C3H5, major); 2.72 (m, 2H, terminal allyl –C3H5,minor)
5.26 (m, 1H, central allyl, minor); 5.51 (m, 1H, central allyl, major);
other peaks were not resolved.
4.6. Synthesis of [(g3-1-Me-C3H4)Pd(j2-P,P0-3)](PF6) (3b)
Starting materials: [(g3-1-Me-C3H4)PdCl]2 (15 mg, 4 ꢂ 10ꢁ5
mol); NH4PF6 (15 mg, 8.8 ꢂ 10ꢁ5 mol) and ligand (3) (94 mg,
8 ꢂ 10ꢁ5 mol). (yield = 0.060 g, 50.5%); m.p. = 215–220 °C (dec.);
31P NMR: (162 MHz, CDCl3): d 126.0 and 129.5; AB pattern, JPP
128.0 Hz [major isomer] 126.8 and 128.3 (broad) [minor isomer].
1H NMR (CDCl3, 400 MHz): d 0.77 (t, 6H, –C2H5CH3), 0.80, 0.83
(2s, 9H each, –C(CH3)3), 1.09 (m, 3H, CH3-allyl), 1.29 (s, 18H,
–C(CH3)3); 1.7 (m, 4H, –C2H5CH3), 3.30 (2d, 2H, ArCH2Ar), 3.55
(m, 2H, terminal allyl), 3.83 and 4.05 (2m, 4H, –C2H5CH3), 4.8–
5.0 (4d, 4H, ArCH2Ar), 5.05 (m, H, central allyl), 6.42 and 6.48
(2s, 4H, m-ArH, calixarene); 6.9–7.6 (m, 16H, biphenol ArH, 4H
m-ArH-calixarene). Elemental Anal. Calc. for C70H89O8P3PdF6: C,
61.3; H, 6.5. Found: C, 62.2; H, 6.3%.
4.13. Synthesis of [(g3-1,3-Ph2-C3H3)Pd(j2-P,P0-4)](PF6) (4b)
Starting materials: [(g3-1,3-Ph2-C3H3)PdCl]2 (26 mg, 4 ꢂ
10ꢁ5 mol); NH4PF6 (15 mg, 8.8 ꢂ 10ꢁ5 mol) and ligand (4) (94 mg,
8 ꢂ 10ꢁ5 mol). (yield = 0.052 g, 40%). m.p. = 192–200 °C (dec.);
31P{1H} NMR (CDCl3, 162 MHz): d = 125.6(s); 1H NMR (CDCl3,
400 MHz): d = 0.81 (t, 6H, –C2H5CH3); 0.91 and 1.22 (2s,
18H + 18H, –C(CH3)3); 1.82 (m, 4H, –C2H5CH3); 2.98, 3.84, 4.26,
4.67 (4d, 1H each, ArCH2Ar), 3.97 and 5.47 (2d, 2H each, ArCH2Ar);
3.51 and 3.60 (2m, 4H, C2H5CH3); 5.22 (m, 2H, terminal allyl), 6.36
(m, 1H, central allyl); 6.5–8.0 (ArH). Elemental Anal. Calc. for
4.7. Synthesis of [(g3-1-Ph-C3H4)Pd(j2-P,P0-3)](PF6) (3c)
Starting materials: [(g3-1-Ph-C3H4)PdCl]2 (20 mg, 4 ꢂ 10ꢁ5
mol); NH4PF6 (15 mg, 8.8 ꢂ 10ꢁ5 mol) and ligand (3) (94 mg,
8 ꢂ 10ꢁ5 mol). 31P{1H} NMR (CDCl3, 162 MHz):
129.6; JP,P = 147.4 Hz.
d 122.7 and
C
89H95O8P3PdF6: C, 66.6; H, 6.0. Found: C, 66.8; H, 5.5%.
4.8. Synthesis of [(g3-1,3-Ph2-C3H3)Pd(j2-P,P0-3)](PF6) (3d)
4.14. Synthesis of [{(g3-C3H5)Pd(Cl)}(5)] (5a)
Starting materials: [(g3-1,3-Ph2-C3H3)PdCl]2 (26 mg, 4 ꢂ 10ꢁ5
mol); NH4PF6 (15 mg, 8.8 ꢂ 10ꢁ5 mol) and ligand (3) (94 mg,
8 ꢂ 10ꢁ5 mol). 31P{1H} NMR (CDCl3, 162 MHz): d 122.7 (s).
Starting materials: [(g3-C3H5)PdCl]2 (3.5 mg, 1 ꢂ 10ꢁ5 mol); li-
gand 5 (19 mg, 2 ꢂ 10ꢁ5 mol) (yield = 0.010 g, 44.1%); m.p. = 217–
225 °C (dec); 31P{1H} NMR (CDCl3, 162 MHz): d = 148.4 (s) (major
isomer); 126.9 (s) (minor isomer); 1H NMR (CDCl3, 400 MHz):
0.65 (t, 6H, –C2H5CH3), 0.95 (s, 9H, –C(CH3)3), 1.12 (s, 18H,
–C(CH3)3); 1.14 (s, 9H, –C(CH3)3), 1.75 (m, 4H, –C2H5CH3), 1.96
(d, 1H, terminal allyl), 3.18 (d, 2J(H,H) = 13.2 Hz, 2H, ArCH2Ar),
3.35 (d, 2J(H,H) = 15.6 Hz, 1H, ArCH2Ar), 3.43(d, 2J(H,H) = 12.7 Hz,
4.9. Synthesis of [{(g3-C3H5)Pd(Cl)}2(3)] (3e)
To a solution of [(g3-C3H5)PdCl]2 (14 mg, 4 ꢂ 10ꢁ5 mol) in
CH2Cl2 (10 ml) was added
a solution of ligand 3 (47 mg,
4 ꢂ 10ꢁ5 mol) in CH2Cl2 (10 ml) at 0 °C. The reaction mixture was